Table 2.
Results of lymphocyte subsets in patients.
| Immune index groups | Groups | T0 | T1 | T2 | T3 | T4 |
|---|---|---|---|---|---|---|
| CD4+% | Control group | 35.72 ± 4.51 | 30.21 ± 6.21 | 29.87 ± 5.21 | 23.45 ± 5.12 | 28.41 ± 5.12 |
| Research group | 35.72 ± 4.51 | 30.54 ± 5.17 | 30.54 ± 5.17 | 32.81 ± 5.71 | 36.10 ± 5.62 | |
|
| ||||||
| CD8+ | Control group | 28.21 ± 5.14 | 28.01 ± 5.14 | 31.92 ± 6.02 | 32.45 ± 5.17 | 28.45 ± 6.15 |
| Research group | 29.41 ± 5.34 | 28.51 ± 5.24 | 31.36 ± 6.51 | 32.18 ± 5.41 | 29.15 ± 5.91 | |
|
| ||||||
| CD4+/CD8+ | Control group | 1.36 ± 0.23 | 1.04 ± 0.15 | 0.82 ± 0.12 | 0.71 ± 0.14 | 1.03 ± 0.15 |
| Research group | 1.21 ± 0.14 | 1.07 ± 0.14 | 0.94 ± 0.11 | 1.01 ± 0.14 | 1.21 ± 0.14 | |
|
| ||||||
| IL-2 | Control group | 13.41 ± 2.61 | 10.54 ± 5.52 | 7.84 ± 4.11 | 7.51 ± 3.84 | 9.32 ± 3.82 |
| Research group | 13.51 ± 2.54 | 9.26 ± 4.12 | 8.64 ± 3.42 | 9.42 ± 3.14 | 12.12 ± 4.36 | |
|
| ||||||
| sIL-2R | Control group | 648.21 ± 61.21 | 682.21 ± 57.21 | 701.34 ± 46.12 | 681.21 ± 42.21 | 661.1 ± 50.1 |
| Research group | 650.12 ± 62.41 | 670.63 ± 56.82 | 694.81 ± 83.72 | 681.42 ± 49.62 | 661.6 ± 50.5 | |
Red data indicate a comparison with T0, P < 0.05; italics indicates a comparison with the control group, P < 0.05.